Presentation of Complete Response of Stage IV Pancreatic Cancer by Kleef R et al.


At the conference, CICON 2019 - TRANSLATING SCIENCE INTO SURVIVAL from September 25.-28., 2019 in Paris, Ralf Kleef et al. from Vienna presented a case report on "Complete response of stage IV pancreatic cancer combining dose adapted checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia". This presentation follows several presentations at international academic conferences, listed in the Selected publications and Running clinical trials auf - look at Oncology / 6. Congress abstracts.

Systematic pre-clinical research has revealed the powerful effects of fever-range hyperthermia on anti-cancer immune functions - reviewed in Repasky EA, Evans SS, Dewhirst M (2013): Temperature Matters! And Why it Should Matter to Tumor Immunologists.

It is evident that fever-range hyperthermia cannot act as a monotherapy in cancer therapy, but can probably significantly increase the effects of other immunotherapies. The new approach of a multi-modular therapy, including dose-reduced checkpoint inhibitors and fever-range whole-body hyperthermia, might be one example where one of the most ancient immune stimulating therapies could find its place in modern cancer therapy.


Print Email

heckel medizintechnik GmbH

Olgastrasse 25
73728 Esslingen

Tel: ++49 (0)711 - 128989 - 0
Fax: ++49 (0)711 - 128989 - 20


Visit us on Facebook

Visit us on Linkedin





Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.